• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    TESARO Recognized At Clinical And Research Awards

    Bryan Mc Govern
    Apr. 07, 2017 09:07AM PST
    Pharmaceutical Investing

    TESARO received two awards from the Clinical and Research (CARE) Awards.

    TESARO (NASDAQ:TSRO) won two awards from the Clinical and Research (CARE) Awards.
    As quoted in the press release:

    Pharma/Biotech Product Development Team of the Year was awarded to the niraparib development team, and the company also received Clinical Research Partnership of the Year with its partner Medidata. The CARE Awards acknowledge and commend excellence across the global clinical research enterprise, recognising individual and corporate achievements. The winners were decided by a distinguished panel of industry experts, and announced at a ceremony on April 5 at The State Room, Boston.

    “TESARO associates are devoted to developing transformative therapies for people bravely facing cancer, and we are thrilled to accept the award for best Pharma/Biotech Product Development Team on behalf of the patients we serve,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO. “We congratulate all of the biopharmaceutical companies that were recognized for the important work being done across our industry to advance patient care.”

    The judges said: “This was a high performing team with an effective plan in place to execute rapid development through intense cross functional collaboration. The team brought this new drug through development to NDA & MAA in under five years, a remarkable achievement.”

    The award winners were chosen from a record number of entries which were adjudicated by a distinguished judging panel. This year’s panel included:

    • Jeffrey M. Bockman, PhD, Vice President, Defined Health
    • Laura Brown, Pharmaceutical Training Consultant, Course Director, University of Cardiff
    • Denis Curtin PhD, Chief Scientific Officer, mProve Health
    • Ken Getz, Director of Sponsored Research Programs & Research Associate Professor, Tufts Center for the Study of Drug Development
    • Laurie A. Halloran, BSN, MS, President, Halloran Consulting
    • Cliff Kalb, President, C. Kalb & Associates
    • Janice McCourt, Vice President of Business Development, Agenus
    • Alison Messom PhD MICR, Chairman of the Board of Directors, Institute of Clinical Research
    • Chad Rubin, Managing Director, The Trout Group

    The CARE Awards is managed by Pharma Intelligence, the world’s leading provider of business intelligence in the pharmacy industry. Pharma Intelligence provides intelligence, news and insight, data and analysis into the complex pharmaceuticals environment for businesses to make informed decisions.

    ICON, the global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, was the headline sponsor for the 2017 CARE Awards.

    To see the full list of winners for the 2017 CARE Awards, visit: https://ibiawards.com/careawards/2017-winners/

    About TESARO
    TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.

    Click here to read the full press release.

    pharmaceutical investingchief scientific officerbusiness developmentmedical device industriesbiopharmaceutical companiesboard of directors
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

    Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×